Canton Man Beats Odds In UConn Clinical Drug Trial – Hartford Courant
Hartford Courant |
Canton Man Beats Odds In UConn Clinical Drug Trial
Hartford Courant Both drugs are forms of immunotherapy, which activates the body's own immune system to fight tumors. A few months after he began, Keytruda was approved to fight certain kinds of lung cancer, after an average 4.3 month improvement in survival of … |
